Multimodal Immune Characterization of Rare Soft Tissue Sarcoma - MIRAS Project from the French Sarcoma Group

What this Trial Is About

Researchers are studying rare subtypes of soft tissue sarcoma to better understand their clinical and biological characteristics. This is a translational, open-label study involving both prospective and retrospective cohorts, aiming to include 500 patients. The study includes patients with localized, locally advanced, or metastatic disease and seeks to evaluate outcomes such as metastasis-free survival and progression-free survival over 60 months. Patients will be enrolled from multiple centers, with 400 patients included prospectively during routine care or clinical studies, and 100 patients identified retrospectively from existing clinical databases. Tumor specimens and blood samples will be collected at diagnosis, after treatment completion or tumor evaluation, and at disease progression. Clinical and biological data will be gathered at baseline and regularly every 2 to 3 months for up to 5 years. Participants will undergo assessments including tumor specimen collection, blood sampling, and regular clinical evaluations to monitor disease progression and treatment effects. Researchers will measure survival outcomes and biological markers such as Cancer-Testis Antigens and the CINSARC signature. The study involves long-term follow-up of up to 60 months per patient to observe overall survival and other key outcomes.

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group